Clinical Trials Directory

Trials / Completed

CompletedNCT00133133

Efficacy and Safety of ALGRX 4975 in the Treatment of Postoperative Pain After Gall Bladder Removal

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects After Open Cholecystectomy

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
40 (planned)
Sponsor
AlgoRx Pharmaceuticals · Industry
Sex
All
Age
20 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Postoperative pain after gall bladder removal can be significant, mobility limiting and extend hospital stay. ALGRX 4975 is an ultra-pure form of capsaicin, which is a pain medicine that has the potential for long-term pain relief following a single administration. This study will determine whether ALGRX 4975 can provide pain relief following gall bladder removal.

Detailed description

Postoperative pain after open cholecystectomy can be significant and mobility limiting, causing increased risk of deep venous thrombosis, pulmonary complications, and extended hospital stay. With increasing emphasis on early postoperative mobilization, adequate postoperative pain control is essential. Acute postoperative pain is currently managed largely with opioids and co-administration of nonsteroidal anti-inflammatory drugs (NSAIDS). Opioids are highly effective in managing acute postoperative pain, however dosing is often limited by side effects such as respiratory depression, nausea and vomiting, and sedation. NSAIDS are administered to reduce opioid use, but may also have limiting side effects, such as gastrointestinal toxicity and platelet dysfunction. New strategies to manage acute postoperative pain would provide clinical benefit. ALGRX 4975 is an ultra-pure form of capsaicin, which is a pain medicine that has the potential for long-term pain relief following a single administration. This study will determine whether ALGRX 4975 can provide pain relief following open cholecystectomy.

Conditions

Interventions

TypeNameDescription
DRUGALGRX 4975

Timeline

Start date
2005-07-01
Completion
2005-12-01
First posted
2005-08-22
Last updated
2006-12-20

Locations

1 site across 1 country: Serbia and Montenegro

Source: ClinicalTrials.gov record NCT00133133. Inclusion in this directory is not an endorsement.